<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="joint" type="multinuc"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1002" relname="background">Cancer has been a major threat to human health in recent years .</segment>
<segment id="3" parent="1003" relname="preparation">In the past forty years ,</segment>
<segment id="4" parent="1004" relname="concession">even though great efforts have been made ,</segment>
<segment id="5" parent="1006" relname="span">there is still much</segment>
<segment id="6" parent="5" relname="elaboration">to be done</segment>
<segment id="7" parent="1006" relname="circumstance">before a safe therapy is achieved .</segment>
<segment id="8" parent="1007" relname="contrast">Currently , chemotherapy and radiotherapy are still the main therapeutic methods for cancer .</segment>
<segment id="9" parent="1008" relname="joint">However , most of the anticancer drugs have toxic side effects .</segment>
<segment id="10" parent="1010" relname="span">Therefore , it is critical to develop novel anticancer drugs</segment>
<segment id="11" parent="10" relname="elaboration">that have no toxic side effects on other tissues or organs in vivo ,</segment>
<segment id="12" parent="1011" relname="joint">and only target the lesion area .</segment>
<segment id="13" parent="1014" relname="attribution">Compared with traditional chemotherapeutic drugs ,</segment>
<segment id="14" parent="1014" relname="span">the nano-anticancer drug therapy has potential application prospects</segment>
<segment id="15" parent="14" relname="elaboration">in curing cancer diseases .</segment>
<segment id="16" parent="1015" relname="joint">One of the major concerns about the nano-anticancer drugs is the drug-delivery vector .</segment>
<segment id="17" parent="1017" relname="joint">The ideal delivery vector should possess such characteristics as a high drug-loading capacity , low immunogenicity , low toxicity , better shelf-life , and water solubility ,</segment>
<segment id="18" parent="1018" relname="span">and it should have the potential</segment>
<segment id="19" parent="18" relname="purpose">to be further modified .</segment>
<segment id="20" parent="1021" relname="span">Synthetic polymers , such as , chitosan , polyetherimide</segment>
<segment id="21" parent="20" relname="elaboration">( PEI ) ,</segment>
<segment id="22" parent="1023" relname="span">poly(lactic-co-glycolic acid )</segment>
<segment id="23" parent="22" relname="restatement">( PLGA ) ,</segment>
<segment id="24" parent="1025" relname="span">polyamidoamine</segment>
<segment id="25" parent="24" relname="elaboration">( PAMAM ) ,</segment>
<segment id="26" parent="1027" relname="span">and poly-l-lactic acid</segment>
<segment id="27" parent="26" relname="restatement">( PLA )</segment>
<segment id="28" parent="1026" relname="same_unit">have been widely used in gene- and drug-delivery systems .</segment>
<segment id="29" parent="1029" relname="span">However , stability of sustained-release formulations in aqueous solution , long delivery times , and low delivery efficiency are only a small part of the challenges</segment>
<segment id="30" parent="29" relname="elaboration">highlighted by researchers .</segment>
<segment id="31" parent="1031" relname="span">Dendrigraft</segment>
<segment id="32" parent="1034" relname="span">poly-l-lysines</segment>
<segment id="33" parent="32" relname="restatement">( DGL )</segment>
<segment id="34" parent="1035" relname="span">have emerged as a new kind of synthetic polymer</segment>
<segment id="35" parent="1036" relname="joint">consisting of lysine</segment>
<segment id="36" parent="1037" relname="span">and have been employed as drug- or gene-delivery carriers ,</segment>
<segment id="37" parent="1038" relname="span">due to their biodegradability and rich external amino groups</segment>
<segment id="38" parent="37" relname="elaboration">that can encapsulate drugs by the emulsion crosslinking method or plasmid DNA through electric interactions .</segment>
<segment id="39" parent="1039" relname="joint">Besides their biodegradability ,</segment>
<segment id="40" parent="1041" relname="span">they can also be modified with targeting ligands and polyethylene glycol</segment>
<segment id="41" parent="40" relname="elaboration">( PEG ) ,</segment>
<segment id="42" parent="1040" relname="same_unit">thereby rendering vectors with targeting properties and long circulation .</segment>
<segment id="43" parent="1043" relname="span">As yet , there are only a few ways</segment>
<segment id="44" parent="43" relname="elaboration">available for targeted delivery of anticancer drugs .</segment>
<segment id="45" parent="1047" relname="attribution">Recently , a report showed</segment>
<segment id="46" parent="1047" relname="span">that VAR2CSA ,</segment>
<segment id="47" parent="1048" relname="span">which is exposed on the membrane of Plasmodium falciparum infected red blood cells</segment>
<segment id="48" parent="47" relname="elaboration">( iRBC ) ,</segment>
<segment id="49" parent="1049" relname="span">could bind to 90 % of tumors ,</segment>
<segment id="50" parent="1050" relname="span">which was verified</segment>
<segment id="51" parent="50" relname="means">by running immunohistochemistry on a tumor-tissue array .</segment>
<segment id="52" parent="1051" relname="joint">Therefore , VAR2CSA is becoming an attractive target for anticancer drugs â€™ development .</segment>
<segment id="53" parent="1054" relname="span">P. falciparum infection during pregnancy results in the sequestration of iRBC in the placenta</segment>
<segment id="54" parent="1055" relname="span">by adhering to a distinct type of chondroitin sulfate A</segment>
<segment id="55" parent="54" relname="restatement">( CSA )</segment>
<segment id="56" parent="1056" relname="span">exclusively</segment>
<segment id="57" parent="56" relname="elaboration">expressed on trophoblast via VAR2CSA .</segment>
<segment id="58" parent="1057" relname="joint">Short continuous regions of VAR2CSA with affinity for multiple types of CSA were defined .</segment>
<segment id="59" parent="1060" relname="span">A 28 amino acids placenta CSA-binding peptide</segment>
<segment id="60" parent="59" relname="restatement">( plCSA-BP )</segment>
<segment id="61" parent="1059" relname="same_unit">from the VAR2CSA region was recently tested as a guide peptide for targeted delivery of doxorubicin to choriocarcinoma .</segment>
<segment id="62" parent="1062" relname="span">However , whether it could be used</segment>
<segment id="63" parent="62" relname="purpose">to modify the DGL and its bioactivity after the modification was not evaluated .</segment>
<segment id="64" parent="1063" relname="joint">The immunosuppressive , antimalarial , and pro-cytotoxic bacterial prodigiosin was recently described as a potent antimetastatic and anticancer agent .</segment>
<segment id="65" parent="1065" relname="span">It can induce apoptosis in a wide range of cancer cell lines ,</segment>
<segment id="66" parent="65" relname="elaboration">including hematopoietic cancer , breast cancer , gastric cancer , colon cancer , lung cancer , and rat hepatocellular carcinoma cell lines ,</segment>
<segment id="67" parent="1067" relname="span">with no marked toxicity in nonmalignant cells .</segment>
<segment id="68" parent="1068" relname="span">However , prodigiosin has not been reported for the treatment of choriocarcinoma yet .</segment>
<segment id="69" parent="1069" relname="span">It is selective</segment>
<segment id="70" parent="1070" relname="span">in promoting apoptosis of malignant tumor cells ,</segment>
<segment id="71" parent="70" relname="elaboration">rendering prodigiosin a promising anticancer agent .</segment>
<segment id="72" parent="1072" relname="span">The antitumor mechanism of prodigiosin is still unclear , especially in regard to newly acquired prodigiosin</segment>
<segment id="73" parent="72" relname="elaboration">produced by a small number of microorganisms , including Serratia marcescens and other bacteria , such as Streptomyces griseoviridis , Serratia spp. , Zooshikellarubidus , Vibrio sp. , Actinomycetes , and Hahella chejuensis .</segment>
<segment id="74" parent="1074" relname="preparation">Research on the mechanism of bacterial origin</segment>
<segment id="75" parent="1075" relname="preparation">prodigiosin is very important for clinical application and drug development .</segment>
<segment id="76" parent="1077" relname="span">In this study ,</segment>
<segment id="77" parent="1078" relname="joint">to develop a new type of targeted drug delivery carrier material</segment>
<segment id="78" parent="1078" relname="joint">and investigate the anticancer mechanism of prodigiosin ,</segment>
<segment id="79" parent="1079" relname="span">we first used plCSA-BP as a guide peptide</segment>
<segment id="80" parent="1080" relname="span">to coat on the DGL vector for cancer-cell-targeted delivery of prodigiosin</segment>
<segment id="81" parent="80" relname="elaboration">produced from Serratia marcescens subsp . lawsoniana HDZK-BYSB107 .</segment>
<segment id="82" parent="1081" relname="joint">Then , we tested the binding ability of the newly developed DGL/CSA-PNPs and its anticancer effect in vitro on a JEG3 choriocarcinoma cell line and in vivo on a tumor model , respectively .</segment>
<segment id="83" parent="1083" relname="span">In addition , the mechanism</segment>
<segment id="84" parent="83" relname="elaboration">responsible for the anticancer effect of targeted nano-prodigiosin was also investigated .</segment>
<segment id="85" parent="1085" relname="attribution">Overall , these findings suggested</segment>
<segment id="86" parent="1085" relname="span">that the DGL/CSA vector is an excellent cancer-specific-drug delivery carrier ,</segment>
<segment id="87" parent="86" relname="elaboration">which has great potential as a novel delivery system for the treatment of cancer .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1001" relname="span"/>
<group id="1003" type="span" parent="1002" relname="span"/>
<group id="1004" type="span" parent="1003" relname="span"/>
<group id="1005" type="span" parent="1004" relname="span"/>
<group id="1006" type="span" parent="1005" relname="span"/>
<group id="1007" type="multinuc" parent="1005" relname="elaboration"/>
<group id="1008" type="multinuc" parent="1007" relname="contrast"/>
<group id="1009" type="multinuc" parent="1008" relname="joint"/>
<group id="1010" type="span" parent="1009" relname="joint"/>
<group id="1011" type="multinuc" parent="1009" relname="joint"/>
<group id="1012" type="multinuc" parent="1011" relname="joint"/>
<group id="1013" type="span" parent="1012" relname="joint"/>
<group id="1014" type="span" parent="1013" relname="span"/>
<group id="1015" type="multinuc" parent="1012" relname="joint"/>
<group id="1016" type="multinuc" parent="1015" relname="joint"/>
<group id="1017" type="multinuc" parent="1016" relname="joint"/>
<group id="1018" type="span" parent="1017" relname="joint"/>
<group id="1019" type="multinuc" parent="1016" relname="joint"/>
<group id="1020" type="multinuc" parent="1019" relname="joint"/>
<group id="1021" type="span" parent="1020" relname="same_unit"/>
<group id="1022" type="multinuc" parent="1020" relname="same_unit"/>
<group id="1023" type="span" parent="1022" relname="same_unit"/>
<group id="1024" type="multinuc" parent="1022" relname="same_unit"/>
<group id="1025" type="span" parent="1024" relname="joint"/>
<group id="1026" type="multinuc" parent="1024" relname="joint"/>
<group id="1027" type="span" parent="1026" relname="same_unit"/>
<group id="1028" type="multinuc" parent="1019" relname="joint"/>
<group id="1029" type="span" parent="1028" relname="joint"/>
<group id="1030" type="multinuc" parent="1028" relname="joint"/>
<group id="1031" type="span" parent="1030" relname="joint"/>
<group id="1032" type="span" parent="31" relname="elaboration"/>
<group id="1033" type="multinuc" parent="1032" relname="span"/>
<group id="1034" type="span" parent="1033" relname="same_unit"/>
<group id="1035" type="span" parent="1033" relname="same_unit"/>
<group id="1036" type="multinuc" parent="34" relname="elaboration"/>
<group id="1037" type="span" parent="1036" relname="joint"/>
<group id="1038" type="span" parent="36" relname="cause"/>
<group id="1039" type="multinuc" parent="1033" relname="elaboration"/>
<group id="1040" type="multinuc" parent="1039" relname="joint"/>
<group id="1041" type="span" parent="1040" relname="same_unit"/>
<group id="1042" type="multinuc" parent="1030" relname="joint"/>
<group id="1043" type="span" parent="1042" relname="joint"/>
<group id="1044" type="multinuc" parent="1042" relname="joint"/>
<group id="1045" type="multinuc" parent="1044" relname="joint"/>
<group id="1046" type="span" parent="1045" relname="same_unit"/>
<group id="1047" type="span" parent="1046" relname="span"/>
<group id="1048" type="span" parent="46" relname="elaboration"/>
<group id="1049" type="span" parent="1045" relname="same_unit"/>
<group id="1050" type="span" parent="49" relname="elaboration"/>
<group id="1051" type="multinuc" parent="1044" relname="joint"/>
<group id="1052" type="multinuc" parent="1051" relname="joint"/>
<group id="1053" type="multinuc" parent="1052" relname="joint"/>
<group id="1054" type="span" parent="1053" relname="same_unit"/>
<group id="1055" type="span" parent="53" relname="means"/>
<group id="1056" type="span" parent="1053" relname="same_unit"/>
<group id="1057" type="multinuc" parent="1052" relname="joint"/>
<group id="1058" type="multinuc" parent="1057" relname="joint"/>
<group id="1059" type="multinuc" parent="1058" relname="contrast"/>
<group id="1060" type="span" parent="1059" relname="same_unit"/>
<group id="1061" type="multinuc" parent="1058" relname="contrast"/>
<group id="1062" type="span" parent="1061" relname="joint"/>
<group id="1063" type="multinuc" parent="1061" relname="joint"/>
<group id="1064" type="multinuc" parent="1063" relname="joint"/>
<group id="1065" type="span" parent="1064" relname="joint"/>
<group id="1066" type="multinuc" parent="1064" relname="joint"/>
<group id="1067" type="span" parent="1066" relname="joint"/>
<group id="1068" type="span" parent="67" relname="elaboration"/>
<group id="1069" type="span" parent="68" relname="elaboration"/>
<group id="1070" type="span" parent="69" relname="elaboration"/>
<group id="1071" type="multinuc" parent="1066" relname="joint"/>
<group id="1072" type="span" parent="1071" relname="joint"/>
<group id="1073" type="span" parent="1071" relname="joint"/>
<group id="1074" type="span" parent="1073" relname="span"/>
<group id="1075" type="multinuc" parent="1074" relname="span"/>
<group id="1076" type="multinuc" parent="1075" relname="joint"/>
<group id="1077" type="span" parent="1076" relname="same_unit"/>
<group id="1078" type="multinuc" parent="76" relname="purpose"/>
<group id="1079" type="span" parent="1076" relname="same_unit"/>
<group id="1080" type="span" parent="79" relname="purpose"/>
<group id="1081" type="multinuc" parent="1075" relname="joint"/>
<group id="1082" type="multinuc" parent="1081" relname="joint"/>
<group id="1083" type="span" parent="1082" relname="joint"/>
<group id="1084" type="span" parent="1082" relname="joint"/>
<group id="1085" type="span" parent="1084" relname="span"/>
	</body>
</rst>
